Cardiopulmonary Bypass Clinical Trial
Official title:
The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot
Verified date | August 2023 |
Source | National Cardiovascular Center Harapan Kita Hospital Indonesia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Congenital heart disease (CHD) is the most common congenital abnormality found in newborns with Tetralogy of Fallot (TOF) being the most common cyanotic CHD. Total correction of TOF was performed using a cardiopulmonary bypass (CPB) machine. However, the use of CPB has a negative effect that causes inflammation and myocardial injury. Myocardial protection in patients undergoing total correction of TOF surgery is more difficult than other cyanotic CHD due to a hypertrophic right ventricular condition. Dexmedetomidine (DEX) is a selective α-2 adrenergic, which has major effects including hypnosis, sedation, and analgesia as well as cardiovascular effects. The sedation is induced by stimulating the α-2 adrenergic receptor in the locus coeruleus (LC) in the pons cerebri. DEX also increases the level of GABA and Galanin and reduces endogenous norepinephrine. The lower level of endogenous norepinephrine decreases the afterload of the ventricles, increases cardiac output, and reduces myocardial injury as a result. Furthermore, the peripheral effects of DEX can reduce myocardial ischemia-reperfusion (MIR) by inhibiting NF-кB pathway activation and reducing the number of pro-inflammatory cytokines released. Thus, the administration of DEX can prevent myocardial necrosis and apoptosis, also reducing reperfusion injury when using CPB machines. Research related to the effectiveness of administering DEX as a myocardial protector in classic TOF patients undergoing elective total correction cardiac surgery in Indonesia is less reported. The aim of this study is to determine the effectiveness of DEX as myocardial protector in classic TOF patients undergoing elective total correction cardiac surgery.
Status | Completed |
Enrollment | 66 |
Est. completion date | June 10, 2023 |
Est. primary completion date | April 10, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Month to 18 Years |
Eligibility | Inclusion Criteria: - The patient's parents or person in charge is willing to participate in the study - Patients with classic TOF undergoing elective total correction cardiac surgery - Aged 1 month - 18 years old Exclusion Criteria: - The patient experiences a change in the surgical plan from elective to immediate or emergency - Patients with preoperative infection characterized by procalcitonin >0.5ng/mL - Patients with impaired liver function characterized by an increase in Serum Glutamic Oxaloacetic Transaminase (SGOT)/Serum Glutamic Pyruvic Transaminase (SGPT) more than 1.5 times the upper limit of normal - Impaired renal function characterized by creatinine > 2 mg/dL - Patients with coagulation disorders characterized by International Normalized Ratio (INR) > 1.5 Drop-out Criteria: - Duration of CPB and/or Aortic cross-clamp time exceeding 120 minutes - Surgery requires more than two attempts of CPB - Patient fails to wean from CPB - Patient requires ECMO (Extracorporeal Membrane Oxygenator) postoperatively - Patients with postoperative reperfusion injury characterized by pulmonary hemorrhage - Patients with residual lesions in the form of moderate-severe pulmonary stenosis and moderate-severe pulmonary regurgitation. - Patient dies on the operating table |
Country | Name | City | State |
---|---|---|---|
Indonesia | National Cardiovascular Center Harapan Kita Hospital Indonesia | Jakarta |
Lead Sponsor | Collaborator |
---|---|
National Cardiovascular Center Harapan Kita Hospital Indonesia |
Indonesia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serum Troponin I at baseline | Troponin I serum concentration will be measured using ELABSCIENCE E-EL-H0649 reagent (ng/mL) | 5 minutes after induction of anesthesia (T1) | |
Primary | Serum Troponin I at 1 hour after cardiopulmonary bypass | Troponin I serum concentration will be measured using ELABSCIENCE E-EL-H0649 reagent (ng/mL) | 1 hour after cardiopulmonary bypass (T2) | |
Primary | Serum Troponin I at 6 hours after cardiopulmonary bypass | Troponin I serum concentration will be measured using ELABSCIENCE E-EL-H0649 reagent (ng/mL) | 6 hours after cardiopulmonary bypass (T3) | |
Primary | Serum Troponin I at 24 hours after cardiopulmonary bypass | Troponin I serum concentration will be measured using ELABSCIENCE E-EL-H0649 reagent (ng/mL) | 24 hours after cardiopulmonary bypass (T4) | |
Primary | Serum IL-6 at baseline | IL-6 serum concentration will measured using RnD Quantikine D6050 IL-6 reagent (pg/mL) | 5 minutes after induction of anesthesia (T1) | |
Primary | Serum IL-6 at 1 hour after cardiopulmonary bypass | IL-6 serum concentration will measured using RnD Quantikine D6050 IL-6 reagent (pg/mL) | 1 hour after cardiopulmonary bypass (T2) | |
Primary | Serum IL-6 at 6 hours after cardiopulmonary bypass | IL-6 serum concentration will measured using RnD Quantikine D6050 IL-6 reagent (pg/mL) | 6 hours after cardiopulmonary bypass (T3) | |
Primary | Serum IL-6 at 24 hours after cardiopulmonary bypass | IL-6 serum concentration will measured using RnD Quantikine D6050 IL-6 reagent (pg/mL) | 24 hours after cardiopulmonary bypass (T4) | |
Secondary | Cardiac output | Cardiac output will be measured using transthoracic echocardiography (L/min) | 5 minutes after induction of anesthesia (T1), 6 hours (T3), 24 hours (T4), and 48 hours (T5) after cardiopulmonary bypass | |
Secondary | Cardiac Index | Cardiac index will be measured using transthoracic echocardiography (L/min) | 5 minutes after induction of anesthesia (T1), 6 hours (T3), 24 hours (T4), and 48 hours (T5) after cardiopulmonary bypass | |
Secondary | Systemic Vascular Resistance (SVR) | SVR will be measured using transthoracic echocardiography (L/min) | 5 minutes after induction of anesthesia (T1), 6 hours (T3), 24 hours (T4), and 48 hours (T5) after cardiopulmonary bypass | |
Secondary | Serum Lactate | Serum lactate will be measured using an enzymatic method with a blood gas analyzer machine (mmol/L) | 5 minutes after anesthesia induction (T1), and then 1 hour (T2), 6 hours (T3), and 24 hours (T4) after cardiopulmonary bypass | |
Secondary | VIS Score | Vasoinotropic score will be measured using the VIS formula | 1 hour (T2), 6 hours (T3), 24 hours (T4) after cardiopulmonary bypass | |
Secondary | Mechanical ventilation time | Mechanical ventilation time will be measured from the moment the patient arrives at the intensive care unit until the patient is extubated | 3 days (or until the patient is extubated) | |
Secondary | Length of stay in the intensive care unit | Length of stay in the intensive care unit will be measured from the moment the patient is admitted to the intensive care unit after the surgery until discharge from intensive care unit | 7 days (or until the patient is discharge from intensive care unit) | |
Secondary | Mortality | Mortality will be measured as long as patient is hospitalized until 30 days postoperative | 30 days post-operative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04084301 -
Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury
|
N/A | |
Completed |
NCT04062396 -
Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction
|
N/A | |
Completed |
NCT02518087 -
Increased Adsorption Membranes During Cardiopulmonary Bypass
|
N/A | |
Recruiting |
NCT01231776 -
Acupuncture Improves Sleep in Patients Undergoing Cardiopulmonary Bypass
|
N/A | |
Completed |
NCT00747331 -
Fenoldopam and Splanchnic Perfusion During Cardiopulmonary Bypass
|
Phase 4 | |
Terminated |
NCT00176657 -
The Use of HEMOBAG to Salvage Blood After Cardiac Surgery
|
Phase 2 | |
Completed |
NCT00161733 -
Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery
|
Phase 3 | |
Completed |
NCT05537168 -
Bayesian Networks in Pediatric Cardiac Surgery
|
||
Completed |
NCT05525195 -
Influence of Preop Fibrinogen on Blood in Pediatric Cardiac Surgery
|
||
Completed |
NCT04238806 -
Desflurane,Brain Natriuretic Peptide and Cardiac Surgery
|
N/A | |
Completed |
NCT00981474 -
Cerebral Autoregulation Monitoring During Cardiac Surgery
|
N/A | |
Recruiting |
NCT05588011 -
Influence of Oxygenator Selection on Platelet Function and Rotational Thromboelastometry Following Cardiopulmonary Bypass
|
N/A | |
Completed |
NCT02566733 -
Minto Model in Effect Site Mode for Target-Controlled Infusion of Remifentanil During Cardiopulmonary Bypass
|
Phase 4 | |
Terminated |
NCT00385450 -
Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor
|
Phase 1 | |
Completed |
NCT00246740 -
Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting
|
Phase 2 | |
Not yet recruiting |
NCT05075265 -
Pharmacokinetics of Methadone in Adults Undergoing Cardiac Surgery With Extracorporeal Circulation
|
||
Recruiting |
NCT04296071 -
Neutrophil Phenotypic Profiling and Acute Lung Injury in Patients After Cardiopulmonary Bypass (CPB)
|
||
Active, not recruiting |
NCT04133740 -
Oxygenation Targets in Cardiac Surgery Patients - a Before-and-after Study
|
Phase 4 | |
Completed |
NCT05033236 -
Platelets and Complement Activation in Coronary Artery Bypass Graft Surgery (CABG)
|
||
Completed |
NCT02979158 -
Preoperative Dual Antiplatelet Therapy: Platelet Function and Influence of Cardiopulmonary Bypass
|
N/A |